London School Joins Always Active Uniform Pilot to Combat Childrens Inactivity and Obesity Levels
Wednesday 1 October, 2025 Reception pupils at Harbinger Primary School received free…
Novo Nordisks oral semaglutide 25 mg (Wegovy in a pill*) delivered 16.6% weight loss in people with obesity in a newly published study
Oral semaglutide 25 mg (the once-daily pill formulation of Wegovy®) achieved significant…
People taking Novo Nordisks Wegovy experienced reduced food noise and boosted mental well-being
Results from a real-world survey suggest that semaglutide for weight management (Wegovy®)…
Novo Nordisks Wegovy cuts risk of heart attack, stroke or death by 57% compared to tirzepatide in real-world study of people with obesity and cardiovascular diseas
Compared with tirzepatide, Wegovy® (semaglutide 2.4 mg) showed a significant 57% greater…
Aon Announces Strategic Investment in eMed to Scale GLP-1 Population Health Platform
Strategic investment is accelerating the transformation of employer-focused obesity solutions to boost…
Rhythm Pharmaceuticals Presents Data on MC4R Agonists Setmelanotide and Bivamelagon at ENDO 2025
- Presentations highlight clinically meaningful reductions in BMI in patients with acquired…
Novo Nordisk A/S: CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in New England Journal of Medicine
Data presented simultaneously at the American Diabetes Association’s® 85th Scientific Sessions, showed…
BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific Sessions
June 21, 2025 18:00 ET Â | Source: BioAge Labs, Inc. Treatment with…
Verdiva Bio to Present New Data Highlighting Once-Weekly Potential of Its Investigational Oral Obesity Candidates at the ADA 85th Scientific Sessions
Phase 1 data evaluating VRB-101, Verdiva Bio’s cAMP-biased oral GLP-1RA, provides proof…
Novo Nordisk: Higher dose of Wegovy provided average weight loss of 21% in people with obesity with a third achieving 25% or more according to data presented at ADA
Higher dose of Wegovy® provided average weight loss of 21% in people…